疫苗对高流行地区异性恋人群中淋病奈瑟菌感染率的潜在影响
本研究建立数学模型评估假设性淋病疫苗对南非高流行地区(约3%)15-49岁异性恋人群淋病奈瑟菌感染率的影响。模型预测,在年接种率10%、疫苗预防感染的效力25%、保护期5年且覆盖全人群的条件下,10年内感染率可降低约50%;若仅接种15-24岁人群,同等条件下全人群感染率降低25%。仅针对高活跃人群接种所需累计接种剂次约为全人群策略的1/3,效率更高。
要点
- 年接种率10%、效力25%、保护期5年且覆盖15-49岁全人群时,10年内淋病奈瑟菌感染率可降低约50%。
- 同等疫苗特性下仅接种15-24岁人群,全人群感染率降低25%。
- 仅针对高活跃人群接种与全人群接种的感染率降幅相似,但前者累计接种剂次约低3倍。
核心结论
- 在高流行异性恋人群中,即使年接种率中等且疫苗效力部分,提供淋病疫苗仍可使淋病奈瑟菌感染率大幅下降。
研究设计与样本
- 建立15-49岁异性恋人群淋病奈瑟菌传播的数学模型,按年龄和性别分层,并利用南非的感染率与性行为数据校准。
- 模型评估不同疫苗特性及不同年龄组接种策略对全人群淋病奈瑟菌感染率的影响。
主要发现
- 年接种率10%、疫苗预防感染效力25%、保护期5年且覆盖全部15-49岁人群时,模型预测10年内淋病奈瑟菌感染率可降低约50%。
- 同等疫苗特性与接种率下仅接种15-24岁人群,全人群感染率预测降低25%。
- 仅针对高活跃人群接种与全人群接种在同时期内感染率降幅相似,但前者使全人群感染率降低50%所需的累计接种剂次约为后者的1/3。
关键数值与推荐
- 年接种率10%、疫苗预防感染效力25%、保护期5年、覆盖全部15-49岁人群:10年内感染率降低约50%。
- 同等疫苗特性与接种率下仅接种15-24岁人群:全人群感染率降低25%。
- 仅针对高活跃人群接种使全人群感染率降低50%的累计接种剂次约为全人群策略的1/3。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Treatment of Neisseria gonorrhoeae is under threat with the emergence and spread of antimicrobial resistance. Thus, there is a growing interest in the development of a gonorrhoea vaccine. We used mathematical modelling to assess the impact of a hypothetical vaccine in controlling gonorrhoea among heterosexuals living in a setting of relatively high N. gonorrhoeae prevalence (∼3 %). METHODS: We developed a mathematical model of N. gonorrhoeae transmission among 15-49-year-old heterosexuals, stratified by age and sex, and calibrated to prevalence and sexual behaviour data from South Africa as an example of a high prevalence setting for which we have data available. Using this model, we assessed the potential impact of a vaccine on N. gonorrhoeae prevalence in the entire population. We considered gonorrhoea vaccines having differing impacts on N. gonorrhoeae infection and transmission and offered to different age-groups. RESULTS: The model predicts that N. gonorrhoeae prevalence can be reduced by ∼50 % in 10 years following introduction of a vaccine if annual vaccination uptake is 10 %, vaccine efficacy against acquisition of infection is 25 % and duration of protection is 5 years, with vaccination available to the entire population of 15-49-year-olds. If only 15-24-year-olds are vaccinated, the predicted reduction in prevalence in the entire population is 25 % with equivalent vaccine characteristics and uptake. Although predicted reductions in prevalence for vaccination programmes targeting only high-activity individuals and the entire population are similar over the same period, vaccinating only high-activity individuals is more efficient as the cumulative number of vaccinations needed to reduce prevalence in the entire population by 50 % is ∼3 times lower for this programme. CONCLUSION: Provision of a gonorrhoea vaccine could lead to substantial reductions in N. gonorrhoeae prevalence in a high prevalence heterosexual setting, even with moderate annual vaccination uptake of a vaccine with partial efficacy.
引用
- Padeniya TN, Hui BB, Wood JG, et al. The potential impact of a vaccine on Neisseria gonorrhoeae prevalence among heterosexuals living in a high prevalence setting. Vaccine. 2023. PMID: 37517908. doi:10.1016/j.vaccine.2023.07.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。